TEV-48125
Sponsors
Otsuka Pharmaceutical Co., Ltd., TEVA Pharma
Conditions
Cluster HeadacheMigraine
Phase 2
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine
CompletedNCT03303092
Start: 2017-12-19End: 2019-11-22Updated: 2021-07-29
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
CompletedNCT03303079
Start: 2017-12-19End: 2019-11-30Updated: 2021-06-15
Phase 3
Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine
CompletedNCT03303105
Start: 2017-12-07End: 2020-06-16Updated: 2023-02-17
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled,
Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens
(Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the
Prevention of Chronic Cluster Headache
Active, not recruitingNL-OMON45623
Start: 2017-12-13Target: 20Updated: 2024-02-28
A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled,
Parallel-Group Study Comparing the Efficacy and Safety of 2 Dose Regimens
(Intravenous/Subcutaneous and Subcutaneous) of TEV-48125 versus Placebo for the
Prevention of Episodic Cluster Headache
NL-OMON47278
Target: 20Updated: 2024-02-28
A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety and Efficacy of
TEV-48125 for the Prevention of Cluster Headache
Active, not recruitingNL-OMON49442
Start: 2018-04-03Target: 20Updated: 2024-02-28